Close

Merck (MRK) Announces KEYTRUDA Phase 3 KEYNOTE-045 Met Primary Endpoint; Trial Stopped Early

Go back to Merck (MRK) Announces KEYTRUDA Phase 3 KEYNOTE-045 Met Primary Endpoint; Trial Stopped Early
Merck & Co. (NYSE: MRK) Delayed: 131.78 +0.03 (0.02%)
Previous Close $131.75    52 Week High $65.46 
Open $132.00    52 Week Low $47.97 
Day High $132.42    P/E 89.65 
Day Low $131.08    EPS $1.47 
Volume 4,424,969